Emerging Pharmacotherapies for Diabetic Macular Edema

Table 2

Selected clinical trials of VEGF antagonists in treatment of diabetic macular edema.

Agent (no. patients)	Main outcomes	Reference
Pegaptanib (260)	More favorable outcomes versus sham at 2 years	[43]
Bevacizumab
DRCR phase II (121)	More favorable outcomes versus photocoagulation at 3 weeks	[45]
BOLT study (80)	More favorable outcomes versus photocoagulation at 1 year	[46]
Ranibizumab
READ-2 study (126)	More favorable outcomes versus photocoagulation at 2 years	[53]
DRCR protocol I (691)	Ranibizumab with photocoagulation more favorable than photocoagulation alone at 2 years	[54]
RESTORE study (345)	Ranibizumab with or without photocoagulation more favorable than photocoagulation alone at 1 year	[57]
RISE/RIDE studies (377)	More favorable outcomes versus sham at 2 years	[59]
RESOLVE study (151)	More favorable outcomes versus sham at 1 year	[60]
Aflibercept
DA VINCI study (219)	More favorable outcomes versus photocoagulation at 1 year	[66]